Rasagiline is an FDA-approved Parkinson’s drug that has been shown to improve cognition and holds promise for slowing the progression of Alzheimer’s disease. Dr. Cummings recently completed an ADDF-funded repurposing trial of rasagiline in Alzheimer’s patients. Initial results showed an improvement in brain function measured by neuroimaging. Final analyses of other biomarkers, supported by the Goodes Prize, will support advancing rasagiline into a larger trial that will confirm its effects on cognition.